静脉帕米膦酸治疗住院患者甲状旁腺激素依赖性高钙血症的疗效与安全性
本回顾性病例对照研究在三级医疗中心纳入2013年至2019年住院的血清钙>12 mg/dL成人患者,比较接受帕米膦酸治疗的甲状旁腺激素相关性高钙血症(PTHRH)患者与未治疗者的疗效与安全性。
要点
- 帕米膦酸可有效降低PTHRH患者血清钙,降幅显著大于未治疗者。
- 治疗组无低钙血症或急性肾损伤,但严重低磷血症需补充治疗。
- 用药后应密切监测钙磷代谢,尤其术前使用帕米膦酸者。
核心结论
- 帕米膦酸对甲状旁腺激素依赖性高钙血症有效且安全,但需密切监测钙磷代谢。
研究设计与样本
- 回顾性病例对照研究,在三级医疗中心纳入2013年10月29日至2019年12月17日住院的血清钙>12 mg/dL成人患者。
主要发现
- PTHRH-Pam+组无患者发生低钙血症或急性肾损伤。
- 3例PTHRH-Pam+患者发生严重低磷血症,均经静脉和口服补充后缓解。
关键数值与推荐
- 帕米膦酸中位总剂量为60 mg(范围30-180 mg)。
- 17例患者行甲状旁腺切除术,其中10例术前28天内接受帕米膦酸,术后4例发生低钙血症、3例发生低磷血症。
临床怎么用
- 帕米膦酸可用于中重度PTHRH的降钙治疗,但需密切监测血钙和血磷。
- 出现低磷血症时应及时给予静脉和/或口服磷补充。
- 甲状旁腺切除术前近期使用帕米膦酸者,术后需警惕低钙和低磷血症。
局限性
- 帕米膦酸用于PTHRH属超说明书用药。
- 需更大规模前瞻性研究确立帕米膦酸及其他强效双膦酸盐在中重度PTHRH中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Bisphosphonates are effective for hypercalcemia of malignancy (HOM). Efficacy and safety data for bisphosphonates in parathyroid hormone-related hypercalcemia (PTHRH) are rare, including pamidronate (Pam), which is not indicated for this condition. OBJECTIVE: This work aims to evaluate the efficacy and safety of Pam for moderate-to-severe PTHRH. METHODS: This retrospective case-control study was conducted at a tertiary care medical center. Patients included adults hospitalized with serum calcium levels greater than 12 mg/dL, from October 29, 2013 to December 17, 2019. Etiology was categorized as PTHRH or PTH-independent. Clinical and laboratory data of PTHRH patients treated with Pam (PTHRH-Pam+) were compared to Pam-untreated counterparts (PTHRH-Pam-). RESULTS: Thirty-four patients with 37 hospitalizations for PTHRH (Pam-treated and -untreated) met the inclusion criteria. Pam was given in 24 of 37 cases (64.8%). Admission serum calcium levels for the PTHRH-Pam+ group were higher than for PTHRH-Pam- group (14.4 mg/dL vs 13.0 mg/dL, P = .005). Median total Pam dose was 60 mg (range, 30-180 mg) in the treated group. Serum calcium decreased 3.5 mg/dL for PTHRH-Pam+ vs 1.6 mg/dL for PTHRH-Pam- (P = .003). No PTHRH-Pam+ patients developed hypocalcemia or acute kidney injury. Nadir serum phosphorus levels were lower in the PTHRH-Pam+ vs PTHRH-Pam- group (1.7 mg/dL vs 2.4 mg/dL, respectively, P = .004). Three PTHRH-Pam+ patients developed severe hypophosphatemia; all resolved with intravenous and oral supplementation. Seventeen patients underwent parathyroidectomy, of whom 10 received Pam within 28 days preoperatively. Postoperatively, 4 developed hypocalcemia and 3 hypophosphatemia. CONCLUSION: This study demonstrates that Pam is effective and safe for treating PTHRH, while ensuring close laboratory monitoring of calcium and phosphorus metabolism. Larger, prospective studies are needed to establish the role of Pam and other potent bisphosphonates in moderate-to-severe PTHRH.
引用
- Rosenblum RC, Twito O, Barzilay-Yoseph L, et al. Efficacy and Safety of Intravenous Pamidronate for Parathyroid Hormone-dependent Hypercalcemia in Hospitalized Patients. J Clin Endocrinol Metab. 2021. PMID: 34157125. doi:10.1210/clinem/dgab457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。